Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence (ARIADNE)

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: March 4, 2010
Last updated: November 15, 2011
Last verified: November 2011
The aim of this study is to assess the patient's perception about and willingness to take his or her medication and the influencing factors interfering with taking medication.

Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Survey and Follow-up of the Treatment Adherence and Medication Habits of Early Breast Cancer Patients on Adjuvant Hormonal Therapy With the Aromatase Inhibitor Arimidex

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Percent of patients remaining adherent to therapy with Arimidex [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Questionnaire for factors influencing adherence [ Time Frame: Every 3 months ] [ Designated as safety issue: No ]

Enrollment: 1077
Study Start Date: March 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   Child, Adult, Senior
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Early breast cancer patients on adjuvant aromatase inhibitor

Inclusion Criteria:

  • Early breast cancer
  • Post menopausal
  • Adjuvant hormonal Arimidex therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01081509

Research Site
Balatonfoldvar, Hungary
Research Site
Bekescsaba, Hungary
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Dombovar, Hungary
Research Site
Gyongyos, Hungary
Research Site
Gyor, Hungary
Research Site
Gyula, Hungary
Research Site
Kaposvar, Hungary
Research Site
Kecskemet, Hungary
Research Site
Miskolc, Hungary
Research Site
Mosdos, Hungary
Research Site
Nagyatad, Hungary
Research Site
Nyiregyhaza, Hungary
Research Site
Orfu, Hungary
Research Site
Papa, Hungary
Research Site
Pecs, Hungary
Research Site
Szeged, Hungary
Research Site
Szekesfehervar, Hungary
Research Site
Szekszard, Hungary
Research Site
Szentes, Hungary
Research Site
Szombathely, Hungary
Research Site
Veszprem, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Zirc, Hungary
Sponsors and Collaborators
Principal Investigator: Zsolt Horvath, M.D., Ph.D. Hungarian National Institute of Oncology
  More Information

Responsible Party: AstraZeneca Identifier: NCT01081509     History of Changes
Other Study ID Numbers: NIS-OHU-ARI-2010/1 
Study First Received: March 4, 2010
Last Updated: November 15, 2011
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
early breast cancer
Therapy adherence

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on October 21, 2016